The Silent Signs of Breast Cancer & How to Know Your Cancer Risk With World-Renowned OB-GYN
In this episode of The Mel Robbins Podcast, Dr. Thais Aliabadi discusses personalized cancer prevention and screening strategies for women. Dr. Aliabadi explains how to calculate breast cancer risk using specific tools and emphasizes that most cases occur in women without family history. She outlines age-specific screening protocols tailored to individual risk levels, covering breast, ovarian, uterine, and cervical cancers, and discusses the role of genetic testing and advanced imaging in early detection.
Beyond cancer screening, Dr. Aliabadi addresses broader health concerns including cardiovascular disease, dementia, and metabolic disorders through biomarker testing and preventive measures. Drawing from her own experience as a breast cancer survivor, she stresses the importance of patient self-advocacy within healthcare systems that often dismiss women's concerns. The episode provides practical guidance on navigating medical appointments, requesting appropriate tests, and taking ownership of one's health through knowledge and persistence.
This is a preview of the Shortform summary of the Nov 12, 2026 episode of the The Mel Robbins Podcast
Sign up for Shortform to access the whole episode summary along with additional materials like counterarguments and context.
1-Page Summary
Cancer Prevention and Screening Strategies
Dr. Thais Aliabadi emphasizes personalized cancer prevention and screening protocols, noting that her practice has not lost a single patient to cancer who followed her recommendations.
Calculating Breast Cancer Risk For Prevention
Dr. Aliabadi uses the Tyrer-Cuzick calculator to assess lifetime breast cancer risk, incorporating factors like breast density, hormone use, family history, and biopsy results. She stresses that 85% of breast cancer cases occur in women with no family history, and the average American woman faces a 12.5% lifetime risk. Risk factors including alcohol use, obesity, and dense breast tissue can significantly increase this percentage. Women with a 20% or higher lifetime risk are considered high-risk and need different management. Dr. Aliabadi urges every woman to calculate her risk by age 30.
Tailored Imaging Protocols Based On Risk Stratification
High-risk women should begin imaging at age 30 with 3D mammography, ultrasound, and MRI, since mammography alone is insufficient. For intermediate-risk women (15-20%), Dr. Aliabadi recommends baseline mammogram and ultrasound at 35, with MRI every three years. Low-risk women should start routine mammograms at 40, though Dr. Aliabadi often recommends a baseline at 35. Dense breast tissue, present in 50% of women, makes cancer detection via conventional mammogram difficult and requires additional ultrasound and advanced imaging.
Genetic Testing and Genomic Profiling For Risk Assessment
For women with any family history of breast, ovarian, pancreatic, aggressive prostate, or colon cancer, Dr. Aliabadi conducts genetic testing by age 25. While only 5-10% of breast cancer cases are traceable to major gene mutations, the remaining 90-95% require broader genomic assessment. Whole genome sequencing now provides polygenic risk scores that calculate risk based on many minor genetic variants, enabling more personalized prevention strategies.
Ovarian Cancer Detection Through Imaging and Preventive Interventions
Dr. Aliabadi advocates annual pelvic ultrasound for detecting early-stage ovarian cancers. For patients finished with childbearing and at elevated risk, removal of the fallopian tubes significantly reduces cancer risk through a minimally invasive outpatient procedure. BRCA mutation carriers need more aggressive intervention: both ovaries and fallopian tubes should be removed by age 40.
Uterine Cancer Prevention Through Endometrial Monitoring and Intervention
After menopause, women should have an endometrial lining less than 4 millimeters. Dr. Aliabadi performs annual ultrasounds to monitor uterine lining, often detecting early, stage-one endometrial cancers that dramatically improve survival rates.
Cervical Cancer Elimination Through HPV Vaccination and Screening
Dr. Aliabadi insists that cervical cancer is nearly 100% preventable through HPV vaccination and regular screening. The vaccine is approved for ages 9-46 and is now part of childhood immunizations. Routine Pap smears and HPV testing begin at age 21, and Dr. Aliabadi states, "There is no reason why anyone should ever die of cervical cancer" with the tools available today.
Age-specific Health Screening Protocols and Tests
Dr. Aliabadi emphasizes proactive, decade-specific health screenings for women, urging patients to ask their doctors for critical tests at each life stage.
Baseline Assessments in the Twenties and Thirties
Dr. Aliabadi recommends all women aged 18-20 get a baseline AMH blood test to assess ovarian reserve, allowing for informed reproductive planning. By age 25, she advocates a baseline hormone panel including [restricted term], prolactin, DHEAS, and thyroid profile. Between ages 28 and 32, Dr. Aliabadi strongly encourages discussion of egg freezing for women not planning to conceive soon, as this is when eggs are healthiest. Each cycle costs between $10,000 and $35,000.
Mid-thirties Through Forties: Cancer Screening and Perimenopausal Monitoring
At age 30, Dr. Aliabadi calculates each patient's lifetime breast cancer risk. By age 35, even low-risk women should undergo baseline mammogram and ultrasound. Women in their mid-30s to late 40s should watch for perimenopausal symptoms, which can start as early as 35 and manifest as irritability, hot flashes, insomnia, and weight changes. In a woman's 40s, Dr. Aliabadi obtains a baseline bone density scan, as the greatest bone loss occurs in the first five years after menopause. She advises all women get a baseline colonoscopy at age 45, or ten years before the age a relative was diagnosed if family history exists.
Post-Menopausal Years: Longevity-Focused Comprehensive Evaluation
For post-menopausal women, hormone replacement therapy is considered safe without contraindications. Dr. Aliabadi recommends genetic testing for the ApoE4 variant to assess Alzheimer's risk, and annual pelvic ultrasound to screen for gynecologic malignancies, as early detection dramatically improves outcomes.
Universal Annual Well-Woman Visit Components Across all Ages
Dr. Aliabadi stresses the importance of annual pelvic ultrasound, Pap smear and HPV co-testing, and genetic testing referrals for women with family cancer history.
Longevity and Disease Prevention Beyond Cancer
Dr. Aliabadi emphasizes early diagnosis and prevention for heart disease, stroke, dementia, and metabolic disorders.
Cardiovascular Risk Assessment Through Apolipoprotein B Measurement
Dr. Aliabadi highlights ApoB as a crucial but often overlooked marker for cardiovascular risk. ApoB quantifies atherogenic particles that contribute to plaque buildup, making it more predictive of heart attack risk than LDL or standard cholesterol measurements. For optimal heart health, Dr. Aliabadi recommends women aim for ApoB levels below 60 mg/dL, and ideally below 40 mg/dL for maximum lifespan. She notes that many healthy women can still have ApoB in the hundreds, silently increasing cardiovascular risk. Lipoprotein(a), a genetic component affecting about 20% of individuals, significantly raises the likelihood of early heart attacks and warrants aggressive management. For accurate testing, fasting is essential and Dr. Aliabadi directs patients to specialized centers.
Dementia Risk Identification and Prevention Through Biomarker Testing
Dr. Aliabadi recommends ApoE4 testing for women, as carrying this allele increases Alzheimer's and dementia risk. Early knowledge enables adoption of personalized prevention strategies before cognitive impairment appears. She also checks homocysteine levels, as elevated levels indicate impaired methylation and increased dementia risk—high-risk women benefit from methylated B-vitamin supplementation. For those genetically predisposed, Dr. Aliabadi emphasizes consistent exercise, at least seven hours of sleep nightly, omega-3 supplementation, and avoiding processed foods. She notes that starting hormone therapy within seven years of menopause for ApoE4 carriers can significantly reduce Alzheimer's risk.
Comprehensive Metabolic and Endocrine Assessment for Overall Health
Dr. Aliabadi advises early screening for hemoglobin A1c in overweight women, even in their 20s and 30s, to catch prediabetes before symptoms develop. She recommends women establish baseline thyroid panels as young adults for early detection of autoimmune thyroid diseases, protecting metabolism, mood, and comprehensive health.
Patient Advocacy and Healthcare Navigation
Dr. Aliabadi, a breast cancer survivor, highlights the urgent need for patients to become empowered advocates for their own health, arguing that current healthcare systems often fail to provide adequate screenings.
Recognizing and Overcoming Dismissive Medical Care
Dr. Aliabadi insists that many women are dismissed within the healthcare system, with symptoms frequently attributed to anxiety or stress without proper testing. This approach delays critical diagnoses, including cancer. She advises that normal lab results do not always mean a patient is healthy if symptoms persist. Even as a health professional, Dr. Aliabadi experienced repeated dismissal from her own doctors and was labeled "crazy" for persisting. Only by refusing to accept reassurances and seeking further imaging did she receive a procedure that likely saved her life. She emphasizes seeking second or third opinions if unheard or dismissed.
Taking Ownership of Personal Health Advocacy
Dr. Aliabadi stresses taking responsibility as a health advocate. Given brief medical appointments, she suggests writing a comprehensive list of concerns, risk factors, and necessary questions before meeting a doctor. She reinforces that women should not simply accept standard recommendations or a doctor's first response, and should request specific tests when concerned. Understanding family history and how to calculate lifetime risk is crucial in advocating for appropriate care.
Empowerment Through Knowledge and Self-Awareness
Aliabadi urges women to know their bodies thoroughly—including breast appearance, menstrual cycles, energy, and mood stability. Knowing what is normal allows women to detect deviations and advocate for timely evaluation. She warns against normalizing symptoms like bloating or pain, which may signal underlying disease. Dr. Aliabadi urges women to inform themselves, fight for appropriate care, and refuse to downplay their needs. She reiterates that no one cares more about an individual's health than they do themselves, and that education is the foundation of effective self-advocacy.
1-Page Summary
Additional Materials
Counterarguments
- The assertion that following Dr. Aliabadi’s recommendations prevents all cancer deaths in her practice is anecdotal and not supported by peer-reviewed, large-scale studies; individual outcomes may not generalize to broader populations.
- Universal early screening protocols (e.g., baseline mammograms or ultrasounds at age 35 for low-risk women) are not currently recommended by major guidelines such as the U.S. Preventive Services Task Force (USPSTF) or American Cancer Society, which base recommendations on balancing benefits and harms (e.g., overdiagnosis, false positives, unnecessary biopsies).
- Routine annual pelvic ultrasounds for ovarian cancer screening in average-risk women are not supported by evidence and are not recommended by organizations like the American College of Obstetricians and Gynecologists (ACOG) due to lack of proven mortality benefit and risk of unnecessary interventions.
- The cost and accessibility of advanced genetic testing, whole genome sequencing, and frequent imaging may not be feasible or necessary for all patients, potentially increasing healthcare disparities.
- The recommendation for universal AMH testing and hormone panels in young women is not supported by current reproductive medicine guidelines, as these tests are not always predictive of future fertility or necessary for all women.
- Aggressive interventions such as prophylactic removal of fallopian tubes or ovaries in women without high-risk mutations (e.g., BRCA) are not standard practice and may expose women to unnecessary surgical risks.
- The claim that cervical cancer is "nearly 100% preventable" may overlook barriers to vaccination and screening access, as well as rare cases of vaccine failure or non-HPV-related cervical cancers.
- The recommendation for annual Pap smear and HPV co-testing is not aligned with current guidelines, which suggest less frequent screening intervals for most women to reduce harms from over-screening.
- The use of polygenic risk scores for breast cancer risk assessment is still emerging and not yet widely validated or incorporated into standard clinical practice.
- The recommendation for hormone replacement therapy (HRT) as "safe" for all postmenopausal women without contraindications may not account for individual risks and the nuanced findings of large studies (e.g., Women's Health Initiative), which suggest HRT should be individualized.
- The emphasis on patient self-advocacy is important, but may place undue burden on patients and does not address systemic issues in healthcare delivery or provider education.
- The recommendation for baseline colonoscopy at age 45 for all women is not universally endorsed; some guidelines recommend starting at 45, while others suggest individualized risk assessment.
- The suggestion that ApoB should be below 60 mg/dL (or 40 mg/dL) for all women is more aggressive than most cardiology guidelines, which typically recommend individualized targets based on overall cardiovascular risk.
- Routine genetic testing for ApoE4 in asymptomatic individuals is not currently recommended by major neurology or geriatrics organizations due to limited actionable interventions and potential for anxiety or discrimination.
- The high cost of egg freezing may not be accessible to many women, and the procedure does not guarantee future pregnancy, which should be clearly communicated.
Actionables
- you can create a personal health timeline by mapping out your age-based screening and prevention milestones on a calendar or planner, including reminders for when to schedule specific tests, vaccinations, and check-ins based on your risk factors and family history; this helps you stay proactive and organized about your health management without relying solely on memory or annual checkups.
- a practical way to advocate for yourself is to prepare a one-page health summary before each medical appointment, listing your symptoms, family history, previous test results, and specific questions or requests for tests; bring two copies—one for you and one for your provider—to ensure your concerns are clearly communicated and documented.
- you can track subtle changes in your body by keeping a monthly self-check journal, noting observations about your breasts, menstrual cycles, mood, energy, and any unusual symptoms; use this record to spot patterns or new issues early and to provide concrete information when discussing concerns with healthcare professionals.
Get access to the context and additional materials
Cancer Prevention and Screening Strategies
Dr. Thais Aliabadi emphasizes the importance of personalized cancer prevention and screening protocols, stating that by understanding and following specific strategies, individuals may save their own lives or those of loved ones. Her practice, which meticulously applies these protocols, has not lost a single patient to cancer who adhered to her recommendations.
Calculating Breast Cancer Risk For Prevention
Dr. Aliabadi uses the Tyrer-Cuzick calculator to assess a woman's lifetime breast cancer risk. This tool incorporates multiple factors: height, weight, breast density (determined by breast imaging), age at menarche and menopause, hormone use, biopsy results, and family cancer history. The process is quick—entering the relevant data takes about two minutes.
Breast cancer risk increases with certain factors: alcohol use, obesity, atypical biopsy history, previous chest radiation, and dense breast tissue. Dr. Aliabadi highlights her own experience as an example: without risk factors or family history, she discovered her risk was 37% after an atypical biopsy, prompting her to pursue preventive surgery.
Personalized risk assessment is crucial, as 85% of breast cancer cases occur in women with no family history. The average American woman faces a 12.5% lifetime risk, but this can rise with the previously mentioned factors. A lifetime risk of 20% or greater places a woman in the high-risk category, necessitating different management. Dr. Aliabadi urges every woman to calculate her risk by age 30, and especially between ages 25 and 30.
Tailored Imaging Protocols Based On Risk Stratification
Women classified as high risk (20% or higher lifetime risk) should begin breast imaging at age 30, instead of the usual 40. The imaging regimen for these women includes 3D mammography, breast ultrasound, and MRI, since mammography alone is insufficient for high-risk individuals. Fifty percent of women have dense breast tissue, which itself raises cancer risk and makes detection via conventional mammogram difficult—dense tissue appears white, as does cancer, making differentiation challenging. Therefore, ultrasound and advanced imaging are essential in these scenarios.
For intermediate-risk women (15–20% risk), Dr. Aliabadi recommends a baseline mammogram and ultrasound at age 35, with MRI added every three years.
For low-risk women, routine mammograms start at 40, but Dr. Aliabadi often recommends a baseline at 35. Women with dense breasts in either category should also have ultrasounds.
To ensure insurance coverage for MRI in high-risk women, the doctor’s order must specify a “high lifetime risk” designation.
Genetic Testing and Genomic Profiling For Risk Assessment
For women with any family history of breast, ovarian, pancreatic, aggressive prostate, or colon cancer, Dr. Aliabadi conducts genetic testing by age 25. There are 11 major gene mutations directly linked to breast cancer; however, only 5–10% of breast cancer cases are traceable to such mutations. The remaining 90–95% require broader genomic assessment, often beyond what family history reveals.
Whole genome sequencing now provides polygenic risk scores, calculating risk based on the sum of many minor genetic variants, even in the absence of classic mutations. Dr. Aliabadi’s own high polygenic risk—three times average—was revealed by such sequencing, explaining her high cancer risk despite negative standard genetic tests. This approach allows for more personalized, precise prevention strategies.
Ovarian Cancer Detection Through Imaging and Preventive Interventions
Dr. Aliabadi advocates annual pelvic ultrasound as a standard for detecting early-stage ovarian cancers. Her proactive approach has led to the detection of many stage-one cases, which is uncommon. For patients finished with childbearing and at elevated risk, removal of the fallopian tubes (often the origin of ovarian cancers) significantly reduces cancer risk. The laparoscopic procedure is outpatient, minimally invasive, and typically requires only a short recovery.
For BRCA mutation carriers, more aggressive intervention is needed: both ovaries and fallopian tubes should be removed by age 40, lead ...
Here’s what you’ll find in our full summary
Cancer Prevention and Screening Strategies
Additional Materials
Counterarguments
- While personalized cancer prevention and screening protocols can be beneficial, there is limited large-scale evidence that such individualized approaches universally outperform established population-based guidelines in reducing mortality.
- The claim that Dr. Aliabadi’s practice has not lost any patient to cancer who adhered to her recommendations is anecdotal and may not be generalizable or verifiable in broader clinical practice.
- The Tyrer-Cuzick calculator, while widely used, is not infallible and may overestimate or underestimate risk in certain populations, particularly those underrepresented in the data used to develop the tool.
- Increased imaging and early screening in younger women, especially those at intermediate or low risk, can lead to overdiagnosis, unnecessary anxiety, false positives, and potentially harmful interventions.
- Routine use of advanced imaging (such as MRI) for all high-risk women is not universally endorsed by all medical guidelines due to cost, accessibility, and the potential for overdiagnosis.
- Annual pelvic ultrasound for ovarian cancer screening is not currently recommended by major organizations (such as the US Preventive Services Task Force) for the general population due to lack of evidence that it reduces mortality and concerns about false positives and unnecessary surgeries.
- Prophylactic removal of fallopian tubes or ovaries carries surgical risks and potential long-term health consequences, and should be carefully weighed against individual risk and patient preferences.
- ...
Actionables
- you can create a personal cancer risk timeline by mapping out your age-based screening and prevention milestones on a calendar or digital planner, including reminders for when to schedule risk assessments, imaging, genetic testing, and vaccinations based on your age and family history; this helps you stay proactive and never miss a recommended step.
- a practical way to track and reduce modifiable cancer risk factors is to keep a simple weekly log of your alcohol intake, weight, and exercise, then set small, achievable goals (like swapping one alcoholic drink for a non-alcoholic option or adding a 10-minute walk) and review your progress monthly to see how your choices impact your risk profile.
- you can prepare a pers ...
Get access to the context and additional materials
Age-specific Health Screening Protocols and Tests
Dr. Thaïs Aliabadi emphasizes the importance of proactive, decade-specific health screenings for women. She urges every woman to ask her doctor for critical tests and assessments at each life stage—starting from the late teens and extending into post-menopause—to guide optimal healthcare and prevent conditions before they arise.
Baseline Assessments in the Twenties and Thirties
Baseline AMH Test Recommended for Ages 18-20 to Guide Reproductive Planning and Healthcare
Dr. Aliabadi recommends that all women aged 18 to 20 get a baseline AMH (antimullerian hormone) blood test to assess ovarian reserve. The AMH test, which can be done by a primary care provider, gynecologist, or family practitioner, provides valuable information about the quantity of remaining eggs. While a high or low AMH does not guarantee fertility outcomes, knowing this number early allows for informed reproductive planning.
Hormone Baseline by Age 25: [restricted term], Prolactin, DHEAS, Thyroid Panel for Future Comparison
By age 25, Dr. Aliabadi advocates a baseline hormone panel, including free and total [restricted term], prolactin, DHEAS (a stress-related adrenal hormone), and a comprehensive thyroid profile. These numbers serve as a reference point for interpreting future changes. Additionally, at this age, patients with a family history of cancer should receive genetic testing to screen for hereditary risk.
Egg Freezing Optimal for Women Aged 28-32; Costs $10,000-$35,000 per Cycle
Between ages 28 and 32, Dr. Aliabadi strongly encourages discussion and consideration of egg freezing, especially for women not in a stable relationship or not planning to conceive soon. Egg quality and quantity decline with age, and women with conditions like PCOS or endometriosis are particularly advised to consider this option. The optimal period for freezing eggs is when they are healthiest, typically between ages 28 and 32. Each cycle costs between $10,000 and $35,000.
Mid-thirties Through Forties: Cancer Screening and Perimenopausal Monitoring
Calculate Lifetime Breast Cancer Risk by Age 30 to Guide Screening Start and Imaging Modalities
At age 30, Dr. Aliabadi calculates each patient's lifetime risk of developing breast cancer. Women with a calculated risk over 20% are advised to begin routine imaging—mammograms, ultrasounds, and MRIs—at age 30.
Women's Health: Baseline Mammography, Ultrasound Screening, and Perimenopausal Symptom Vigilance
By age 35, even low-risk women should undergo a baseline mammogram and ultrasound. Women in their mid-30s to late 40s should watch closely for symptoms of perimenopause, which can start as early as 35 for some and manifest as irritability, hot flashes, insomnia, weight changes, hair loss, joint pain, and more. Hormone replacement therapy (HRT), including micronized progesterone and estrogen patches, may be started in symptomatic women without contraindications such as a history of breast cancer.
Establish Baseline Bone Density in 40s to Prevent Post-Menopause Loss
In a woman’s 40s, Dr. Aliabadi obtains a baseline bone density scan to detect risk early and intervene with treatment or lifestyle changes. The greatest bone loss occurs in the first five years after menopause, so starting with strong bones is critical to avoiding osteoporosis.
Women Should Start Colonoscopy at 45, or 10 Years Before the Age at Which a Relative Was Diagnosed if Family History Exists
Dr. Aliabadi advises that all women get a baseline colonoscopy at age 45. Those with a family history of colon cancer should begin screening ten years before the age that their relative was diagnosed—for example, if a relative was diagnosed at 48, screening should start at 38.
Post-Menopausal Years: Longevity-Focused Comprehensive Evaluation
Hormone Therapy Safe for Post-Menopausal Women Without Contraindications
For post-menopausal women, hormone replacement therapy is considered safe if there are no contraindications such ...
Here’s what you’ll find in our full summary
Age-specific Health Screening Protocols and Tests
Additional Materials
Counterarguments
- Many professional medical organizations, such as the American College of Obstetricians and Gynecologists (ACOG), do not recommend routine AMH testing or egg reserve assessment for all women in their late teens or early twenties, as AMH is not a reliable predictor of future fertility for the general population.
- Routine hormone panels ([restricted term], prolactin, DHEAS, thyroid) in asymptomatic women without specific indications are not generally recommended by major guidelines, as abnormal results may not correlate with disease and could lead to unnecessary anxiety or interventions.
- Universal egg freezing is not recommended by most medical societies; it is typically suggested for women with specific medical indications or those undergoing treatments that threaten fertility, rather than as a standard for all women aged 28-32.
- The high cost of egg freezing ($10,000-$35,000 per cycle) and the lack of insurance coverage for elective procedures may make this recommendation inaccessible or impractical for many women.
- Routine breast cancer risk calculation and imaging (mammogram, ultrasound, MRI) before age 40 is not recommended for average-risk women by organizations such as the U.S. Preventive Services Task Force (USPSTF) and ACOG; early imaging may increase false positives and unnecessary biopsies.
- Baseline mammograms and ultrasounds for all women at age 35 are not supported by most guidelines, which typically recommend starting mammography at age 40 for average-risk women.
- Annual pelvic ultrasounds for asymptomatic women are not recommended by ACOG or the USPSTF, as they have not been shown to improve outcomes and may lead to unnecessary interventions due to incidental findings.
- Annual Pap smears are no longer recommended for most women; current guidelines suggest Pap testing every 3 years for women aged 21-29 and Pap plus HPV co-testing every 5 years for women aged 30-65, unless there are specific risk factors.
- Routine genetic testing for cancer risk in all women with a family hist ...
Actionables
- You can create a decade-based health timeline for yourself by listing your current age and mapping out which screenings, tests, and check-ins you’ll need in the next ten years, then set calendar reminders for each milestone so you don’t miss them; for example, if you’re 27, note when to schedule your next hormone panel, breast cancer risk assessment, and bone density scan, and add reminders to your phone or planner.
- A practical way to keep track of your family’s health history is to start a shared digital document with close relatives where everyone can update diagnoses, ages at diagnosis, and relevant genetic information, making it easier to spot patterns and know when to seek early screenings or genetic counseling.
- You can prepar ...
Get access to the context and additional materials
Longevity and Disease Prevention Beyond Cancer
Dr. Thais Aliabadi emphasizes the importance of early diagnosis and prevention in reducing risks for heart disease, stroke, dementia, and metabolic disorders—especially for women seeking both health and longevity.
Cardiovascular Risk Assessment Through Apolipoprotein B Measurement
Apob, a More Accurate Cardiovascular Risk Predictor, Represents the Total Number of Atherogenic Particles in the Bloodstream That Cause Plaque Formation, Exceeding Traditional Cholesterol or Ldl Measurements
Dr. Aliabadi highlights ApoB as a crucial but often overlooked marker for cardiovascular risk. ApoB quantifies the number of atherogenic particles—specifically, LDL, IDL, VLDL, and lipoprotein(a)—that contribute to plaque buildup in arteries, making it more predictive of heart attack risk than LDL or standard cholesterol measurements.
Women Should Target Apob Levels Below 60 For Heart Health and Below 40 For Longevity, as Many Healthy Women Still Have Elevated Levels in the Hundreds
For optimal heart health and longevity, Dr. Aliabadi recommends that women aim for ApoB levels below 60 mg/dL, and ideally below 40 mg/dL for those striving for maximum lifespan. She points out that many women who appear healthy and follow good lifestyles can still have ApoB in the hundreds, silently increasing their cardiovascular risk.
Lipoprotein(a) Elevates Cardiovascular Risk and Apob Levels, Requiring Aggressive Management
Lipoprotein(a), or "Lp(a)," is a genetic component of the ApoB measurement—about 20% of individuals possess elevated Lp(a). This drives higher ApoB and significantly raises the likelihood of early heart attacks, as seen in families with premature cardiovascular events. Since Lp(a) can solely and powerfully elevate a person's risk, it warrants attention and sometimes aggressive management.
Apob Testing: Fast Required, Use Specialized Labs for Accurate Results
For accurate ApoB assessment, fasting is essential. Dr. Aliabadi directs patients to specialized centers such as Cleveland Clinic or Boston Heart for reliable testing, noting that not all laboratories provide precise results. She encourages women to note ApoB on their checklist for fasting blood tests and consult a cardiologist who understands these advanced markers.
Dementia Risk Identification and Prevention Through Biomarker Testing
Apoe4 Testing Identifies Women At Higher Alzheimer's and Dementia Risk, Informing Personalized Prevention to Reduce Incidence Before Cognitive Decline
Dr. Aliabadi recommends ApoE genotyping—specifically, ApoE4 testing—for women, as carrying the ApoE4 allele increases the risk for Alzheimer’s and dementia. Early knowledge enables individuals to adopt personalized prevention strategies before signs of cognitive impairment appear.
Women With High Homocysteine Benefit From Methylated B-Vitamins, as It Indicates Impaired Methylation, Raising Cognitive Decline Risk, Thus a Modifiable Factor
Another biomarker, homocysteine, is routinely checked by Dr. Aliabadi. Elevated homocysteine points to impaired methylation, which increases dementia risk. High-risk women benefit from supplementation with methylated B-vitamins to optimize methylation and lower their cognitive decline risk.
Exercise, Sleep, Om ...
Here’s what you’ll find in our full summary
Longevity and Disease Prevention Beyond Cancer
Additional Materials
Counterarguments
- While ApoB is a strong predictor of cardiovascular risk, major guidelines (such as those from the American College of Cardiology and American Heart Association) still primarily recommend LDL cholesterol as the main target for therapy, and ApoB testing is not universally endorsed or available.
- The specific ApoB targets of <60 mg/dL for heart health and <40 mg/dL for longevity are more aggressive than most guideline recommendations, and there is limited long-term outcome data supporting these exact thresholds for the general population.
- The clinical benefit of aggressively lowering Lp(a) is still under investigation, as there are currently no FDA-approved therapies specifically for Lp(a) reduction, and outcome data are limited.
- Routine ApoE4 genotyping for dementia risk is not currently recommended by most professional societies, as there are no proven interventions that specifically alter risk based on genotype, and knowledge of genotype may cause unnecessary anxiety.
- The evidence supporting methylated B-vitamin supplementation for lowering dementia risk in those with elevated homocysteine is mixed, and not all studies have shown cognitive benefit from lowering homocysteine.
- The recommendation for hormone therapy to redu ...
Actionables
- You can create a personal health tracking chart that logs your ApoB, Lp(a), hemoglobin A1c, and thyroid panel results over time, along with notes on lifestyle changes, to spot trends and discuss them with your healthcare provider at each visit. This helps you visualize your risk factors and see how adjustments in diet, exercise, or supplements may impact your numbers, making it easier to have informed conversations with your doctor.
- A practical way to ensure you get accurate advanced lipid testing is to call local labs ahead of time and ask specific questions about their ApoB and Lp(a) testing methods, then keep a list of labs that meet high standards for future reference. This proactive approach saves time and reduces the risk of inaccurate results, especially if you move or travel frequently.
- You can set up a recurring calendar reminde ...
Get access to the context and additional materials
Patient Advocacy and Healthcare Navigation
Dr. Thais Aliabadi, a renowned women's health advocate and breast cancer survivor, highlights the urgent need for patients, especially women, to become empowered advocates for their own health. She argues that current healthcare systems often fail to provide adequate screenings and proper medical treatment, and that patients must take active steps to protect their well-being.
Recognizing and Overcoming Dismissive Medical Care
Women Face Medical Dismissal, Where Symptoms Are Attributed To Anxiety or Stress Without Tests, Delaying Cancer and Serious Condition Diagnoses
Dr. Aliabadi insists that many women are dismissed within the healthcare system. Symptoms are frequently attributed to anxiety, stress, or insufficient sleep, and conditions are normalized rather than evaluated for underlying disease. This approach delays critical diagnoses, including cancer, as women’s pain and concerns are minimized or ignored. Aliabadi notes that, for many women, the system teaches them to dismiss their own symptoms and normalize discomfort, regardless of its cause or potential seriousness.
Normal Lab Values Don't Rule Out Persistent Symptoms—Women's Health Vigilance Needed
She advises that normal lab results do not always mean a patient is healthy, especially if symptoms persist. Citing her own experience, Aliabadi had regular risk factors and no alarming family history but was ultimately diagnosed with cancer only after she persisted beyond normal lab values and others' reassurances. She urges women to question the dismissal of ongoing symptoms when standard test results appear normal.
Seek Multiple Opinions: Dr. Aliabadi's Experience With Cancer Prevention
Even as a knowledgeable health professional, Dr. Aliabadi experienced repeated dismissal from her own doctors when she sensed there was still breast tissue remaining after her mastectomy. She was told by radiologists and gynecologists that nothing was wrong and was even labeled as "crazy" for persisting. Only by refusing to accept these assurances, continuing to seek further imaging, and looking for a doctor willing to listen, did she ultimately receive a procedure that likely saved her life. She emphasizes that if a woman feels unheard or dismissed, she should seek second or third opinions, and persist until she finds a provider who will take her concerns seriously.
Taking Ownership of Personal Health Advocacy
Maximize 15-minute Visits: Prepare Concerns, Risk Factors, Desired Tests
Dr. Aliabadi stresses taking responsibility as a health advocate. Given the brevity of most medical appointments, she suggests writing a comprehensive list of concerns, personal and family risk factors, and necessary questions or tests before meeting a doctor. Bring this list to maximize the limited time—for example, by ensuring all relevant screenings (like mammograms, ultrasounds, MRIs) are discussed, or by remembering to ask if specific labs, such as ApoB, ApoE4, hormones, bone density, or genetic tests, are necessary.
Women Must Recognize Their Role In Actively Advocating For Their Health Beyond Standard Recommendations
She reinforces that women should not simply accept standard recommendations or a doctor’s first response, especially if it does not address their concerns. It is vital to ask informed questions about family history, risk factors, and which screenings are best suited for personal health profiles. If concerned about specific conditions such as PCOS or endometriosis, women should explicitly request that doctors investigate these possibilities.
Women Should Learn About Risk Factors, Family History, and Screening Options Before Appointments to Ask Informed Questions, Request Specific Tests, and Challenge Resistance To Preventive Care
Understanding family history and how to calculate lifetime risk is crucial in advocating for appropriate care. Dr. Aliabadi describes recalculating her own breast cancer risk and presenting these findings to her medical team in order to ...
Here’s what you’ll find in our full summary
Patient Advocacy and Healthcare Navigation
Additional Materials
Counterarguments
- While patient advocacy is important, not all patients have the resources, health literacy, or confidence to effectively advocate for themselves, potentially leading to increased anxiety or frustration.
- Overemphasis on self-advocacy may inadvertently shift responsibility for systemic healthcare failures onto individual patients rather than addressing institutional shortcomings.
- Encouraging patients to seek multiple opinions and request extensive testing could contribute to overutilization of healthcare resources, increased costs, and potential unnecessary procedures.
- Not all instances of symptom dismissal are due to gender bias; time constraints, diagnostic uncertainty, and the prevalence of benign conditions can also play a role in clinical decision-making.
- Normal lab values are generally reliable indicators for ruling out many serious conditions; persistent skepticism of standard results without clinical justification may undermine trust in medical expertise.
- Some patients may misinterpret or overemphasize minor symptoms, leading to increased healthcare utilization for non-serious issues and potential strain on the system.
- The focus on ...
Actionables
- You can create a personal symptom timeline by jotting down any recurring or unusual symptoms on a calendar or in a notebook, noting when they start, change, or worsen, so you have a clear, objective record to reference during appointments and to spot patterns that might otherwise be dismissed.
- A practical way to prepare for appointments is to draft a one-page health summary that includes your top three current concerns, a brief family health history, and a list of questions you want answered, then bring two copies—one for you and one to hand directly to your provider at the start of the visit to ensure your priorities are addressed.
- You ...
Get access to the context and additional materials
Create Summaries for anything on the web
Download the Shortform Chrome extension for your browser
